TuHURA Biosciences (HURA) Expected to Announce Quarterly Earnings on Thursday

TuHURA Biosciences (NASDAQ:HURA) is expected to be announcing its Q2 2026 resultson Thursday, August 13th. Analysts expect TuHURA Biosciences to announce earnings of ($0.1533) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts expect TuHURA Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TuHURA Biosciences Stock Up 0.9%

Shares of HURA opened at $2.15 on Tuesday. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.90. The company’s fifty day moving average is $2.26 and its two-hundred day moving average is $1.96. The firm has a market cap of $136.91 million, a PE ratio of -3.52 and a beta of -0.01.

Hedge Funds Weigh In On TuHURA Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of HURA. Virtu Financial LLC acquired a new stake in TuHURA Biosciences in the third quarter valued at approximately $26,000. JPMorgan Chase & Co. purchased a new position in shares of TuHURA Biosciences in the second quarter valued at $27,000. Invesco Ltd. purchased a new position in shares of TuHURA Biosciences in the second quarter valued at $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TuHURA Biosciences during the 2nd quarter valued at $31,000. Finally, Bank of America Corp DE acquired a new stake in TuHURA Biosciences during the 4th quarter valued at $59,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

Analysts Set New Price Targets

HURA has been the topic of a number of research analyst reports. Citigroup began coverage on TuHURA Biosciences in a report on Monday, April 27th. They issued an “outperform” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Citizens Jmp began coverage on TuHURA Biosciences in a report on Monday, April 27th. They set a “market outperform” rating and a $9.00 target price for the company. Finally, Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research report on Wednesday, April 15th. They set a “buy” rating for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, TuHURA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.